Allodynia: Why Normal Touch Triggers Nerve Pain

Allodynia is pain caused by a stimulus that would not normally be painful. A light brush across the skin, the weight of clothing, a cool breeze, or gentle pressure can all register as genuinely painful in someone experiencing allodynia. It is classified by the type of stimulus that triggers it, including touch, pressure, pinprick, cold, and heat.¹ The sensation is not imagined or exaggerated in the psychological sense; it reflects real changes in how the nervous system processes sensory information, and it shows up across a surprising range of conditions, from shingles and chemotherapy side effects to migraines and fibromyalgia.

What Allodynia Feels Like and How It Differs From Ordinary Pain

Ordinary pain is a reasonable response to a harmful stimulus. Touch a hot stove and the pain signals that tissue damage is happening. Allodynia breaks that relationship. The stimulus itself is harmless, yet the nervous system treats it as a threat. Someone with allodynia after shingles might wince when a bedsheet brushes their torso. A person mid-migraine might find it painful to rest their head on a pillow or wear a ponytail. It is worth distinguishing allodynia from hyperalgesia, which is an exaggerated pain response to something that is genuinely painful, like a pinprick feeling far worse than it should. Both often coexist, but they represent different flavors of the nervous system going haywire.

The types of allodynia are usually named by the stimulus involved. Dynamic mechanical allodynia, the most commonly discussed form, is triggered by light stroking or brushing across the skin. Static mechanical allodynia comes from gentle sustained pressure. Cold allodynia, where mildly cool temperatures become painful, is especially prominent in chemotherapy patients. These distinctions matter clinically because the underlying nerve fibers and mechanisms differ, which influences which treatments work.

Why the Nervous System Starts Producing Pain From Normal Touch

The short explanation is that the nervous system becomes sensitized. But “sensitized” covers two different processes that can happen at different levels of the pain pathway, and understanding both helps make sense of why allodynia is so stubbornly difficult to treat.

At the spinal cord level, a process called central sensitization causes nerve cells in pain-processing circuits to become hyperexcitable. Neurons that normally only respond to genuinely painful input start responding to signals from touch-sensing nerve fibers. The net effect is that previously harmless sensory inputs get rerouted through pain pathways, producing pain where there should be none.² This is not a simple volume knob being turned up. It involves changes in how receptors on nerve cells behave, a shift in the balance between excitatory and inhibitory signaling, and even physical sprouting of new nerve connections.

Research in animal models of both neuropathic pain and cancer pain has shown that the large-diameter nerve fibers responsible for light touch (called Aβ fibers) undergo measurable changes in how they fire, becoming more excitable than normal. On top of that, these touch-sensing fibers sprout abnormal connections into regions of the spinal cord that normally process pain signals.³ So the wiring diagram itself changes, not just the sensitivity of existing circuits.

The Role of Lost Inhibition

A healthy spinal cord has built-in braking systems that keep pain signals in check. Inhibitory neurotransmitters, particularly GABA and glycine, act like gatekeepers, preventing low-level sensory signals from being interpreted as pain. When that inhibition is lost or weakened, touch signals can slip through into pain pathways. Studies in spinal cord injury models have shown that rats developing allodynia had reduced GABAergic inhibition in the dorsal horn, the region of the spinal cord where sensory signals are first processed.⁴ Blocking GABA or glycine receptors experimentally in otherwise healthy animals produces a similar result: the normal pain-withdrawal reflex starts being triggered by light touch, mimicking the allodynia seen in patients.⁵

Immune cells in the spinal cord also play a part. Microglia, the brain and spinal cord’s resident immune cells, release a signaling molecule called BDNF when activated. That BDNF disrupts the normal inhibitory circuitry in pain-transmitting neurons, essentially removing the brakes from the inside.⁶ This microglia-driven process has become one of the more active areas of pain research, partly because it turns out to work differently in males and females.

Conditions Where Allodynia Commonly Appears

Allodynia is not a disease in itself but a symptom that cuts across many conditions. A few are especially well-studied.

Postherpetic Neuralgia

After a shingles outbreak, the virus can leave lasting damage to sensory nerves. Allodynia is one of the hallmark consequences. A retrospective study of patients with herpetic neuralgia found that about 42% had allodynia, with dynamic allodynia (pain from light stroking) being the most common form. Risk factors included local sweating in the affected area and higher pain intensity, while the presence of scarring was actually associated with lower allodynia risk.⁷ Mouse studies suggest that postherpetic allodynia is linked to selective destruction of small pain-sensing C fibers while larger touch-sensing A fibers remain intact, which may force the nervous system to misinterpret the remaining touch signals as painful.⁸

Migraine

Many people with migraine experience cutaneous allodynia during attacks: the scalp becomes tender, wearing glasses hurts, and even touching the face feels painful. This typically develops as an attack progresses. Throbbing headache pain arrives first as peripheral nerves around the meninges become sensitized, and then allodynia spreads from the head into the referred pain area and sometimes beyond, reflecting sequential sensitization from first-order to second-order and then third-order neurons in the pain pathway.⁹ This progression has practical consequences. Cutaneous allodynia serves as a clinical marker that central sensitization has taken hold during a migraine.¹⁰ Headache specialists sometimes use its presence or absence to guide treatment timing, since some acute medications like triptans work less well once allodynia is established. Central sensitization is thought to play a role not only in acute attacks but also in the chronification of migraine over time.¹¹

Fibromyalgia

Fibromyalgia is essentially a disorder of widespread central sensitization, and allodynia is one of its defining features. A study of fibromyalgia patients found that about 31% showed clear signs of central sensitization based on the presence of abnormal pinprick hyperalgesia or dynamic mechanical allodynia.¹² Central sensitization in fibromyalgia is associated with pain that does not correspond to inflammation or structural damage, which is part of why the condition was historically dismissed as psychosomatic.¹³

Chemotherapy-Induced Cold Allodynia

Oxaliplatin, a platinum-based chemotherapy drug used widely for colorectal cancer, frequently causes cold allodynia as a side effect. Patients find that touching cold objects or being exposed to cool air triggers sharp pain in the hands and feet. The mechanism involves a cold-sensing receptor called TRPM8 on sensory nerve cells. Oxaliplatin’s breakdown product, oxalate, drives overexpression of TRPM8 in the dorsal root ganglion, making those nerve cells abnormally sensitive to cold.¹⁴ Oxalate also disrupts ion channels and calcium signaling in those neurons. A review of medical records from patients receiving oxaliplatin-based chemotherapy found that those already taking calcium channel blockers for other reasons had a lower incidence of acute neuropathy.¹⁵ This has spurred interest in developing targeted therapies. One experimental approach involves a designed peptide that selectively blocks chemical activation of the TRPM8 channel without interfering with its normal cold-sensing function, thereby reducing allodynia without the side effect of disrupted body temperature regulation.¹⁶

How Allodynia Is Measured

There is no blood test for allodynia. Diagnosis depends on bedside sensory testing. The most widely used tools are von Frey monofilaments, thin nylon filaments calibrated to bend at a specific force. Clinicians press increasingly fine filaments against the skin until the patient reports pain, establishing a mechanical pain threshold. In patients with allodynia, pain thresholds measured with von Frey filaments correlate inversely with perceived pain intensity, meaning that the lower the force needed to trigger pain, the worse the patient’s subjective experience.¹⁷

Standardized protocols for quantitative sensory testing go beyond von Frey filaments. A comprehensive battery includes thermal detection and pain thresholds, tests for dynamic mechanical allodynia using a brush, and assessment of pain summation when repeated stimuli are applied.¹⁸ These tests help clinicians characterize the type and severity of sensory dysfunction, which in turn informs treatment choices. For migraine, the assessment is simpler: a doctor may ask whether brushing your hair or resting your head on a pillow hurts during an attack.

Treatment Approaches

Treating allodynia effectively usually means addressing the underlying sensitization, and that is harder than it sounds. No single therapy works for everyone, and the best approach depends on the condition driving the allodynia and the type of sensory abnormality present.

Topical Treatments

For localized allodynia, particularly in postherpetic neuralgia, topical agents avoid the systemic side effects of oral medications. Lidocaine 5% medicated plasters and high-concentration capsaicin 8% patches are both approved for postherpetic neuralgia, with evidence supporting their use in other neuropathic pain conditions as well.¹⁹ The capsaicin 8% patch has shown particularly strong results against dynamic mechanical allodynia. In a head-to-head comparison with oral pregabalin, the capsaicin patch was superior in reducing both the intensity and the area of allodynia. Complete resolution of allodynia occurred in about 24% of patients using the patch versus roughly 12% on pregabalin.²⁰ Capsaicin works by initially overstimulating and then desensitizing the local pain fibers, which is why the patch application itself can be intensely burning for the first hour.

Oral Medications

Pregabalin and gabapentin are among the most commonly prescribed oral medications for neuropathic pain with allodynia. They work by binding to a specific subunit of voltage-gated calcium channels on nerve cells, reducing calcium influx and thereby dampening the release of excitatory neurotransmitters.²¹ Mirogabalin is a newer addition to this class.²² Antidepressants, particularly serotonin-norepinephrine reuptake inhibitors like duloxetine, are also used because they bolster the descending inhibitory pathways from the brain that help dampen pain signals at the spinal level. Opioids are generally avoided for allodynia since they do not address the underlying sensitization and carry well-known risks with long-term use.

Neuromodulation

Transcranial magnetic stimulation (TMS), a noninvasive technique that uses magnetic fields to modulate brain activity, has shown promise for allodynia following spinal cord injury. In animal models, TMS improved mechanical allodynia, cold sensitivity, and thermal hyperalgesia, with the effects persisting beyond the treatment period. Starting treatment earlier after injury produced better pain relief than waiting.²³ Spinal cord stimulation, which uses implanted electrodes to deliver electrical pulses to the spinal cord, is another option for severe refractory cases, though it requires surgery and is reserved for patients who have not responded to other treatments.

Rehabilitation and Sensory Retraining

Graded motor imagery (GMI) is a rehabilitation approach originally developed for complex regional pain syndrome, a condition in which allodynia is often severe. GMI works through a sequence of exercises including left-right discrimination tasks, imagined movements, and mirror therapy, progressively retraining the brain’s body maps. In patients with complex regional pain syndrome, GMI reduced movement pain and normalized overactive responses in the primary sensory cortex.²⁴ Desensitization exercises, in which patients repeatedly expose affected skin to progressively more intense but controlled sensory stimuli, are another approach. A trial in pediatric burn survivors with complex regional pain syndrome found that desensitization therapy was particularly effective at improving sensory thresholds, while GMI was better for pain and mobility overall.²⁵

Sex Differences in How Allodynia Develops

One of the more striking recent discoveries in pain research is that the cellular mechanisms driving allodynia differ between males and females. In male rodents, mechanical allodynia after nerve injury depends heavily on microglia and a signaling molecule called VEGF-A. In females, the same symptom is driven instead by T cells and the hormone leptin. Blocking microglia-derived VEGF-A reversed allodynia in males but not females, while neutralizing leptin reversed it in females but not males.²⁶ Remarkably, transferring female-derived T cells into male animals produced robust allodynia that was leptin-dependent, suggesting the sex difference is tied to the immune cells rather than the nervous system alone.

Despite these different upstream mechanisms, both pathways converge on the same downstream target in the spinal cord. Facilitated excitatory signaling through NMDA receptors in pain-transmitting neurons is consistent between males and females.²⁷ This convergence means the final pain experience may be similar, but the routes to get there are not, which has real implications for drug development. A therapy targeting microglia might work well in men but fail in women, or vice versa. Most pain research historically was conducted in male animals, which may partly explain why some promising drug candidates failed in mixed-sex clinical trials.

What the Brain Does With Allodynic Pain

Brain imaging studies have mapped which regions respond when allodynia is triggered. In patients with postherpetic neuralgia, brushing the affected skin activates a broader and somewhat different brain network compared to the same stimulus on unaffected skin. The allodynic side produces increased activity in the primary sensory cortex and primary motor cortex on the opposite side of the brain, but also recruits unusual responses on the same side, particularly in the secondary somatosensory cortex and insula. Regions linked to spatial attention and motor control also light up, reflecting the brain’s alarm response to a signal it interprets as threatening.²⁸

The insular cortex seems to play a special role. Imaging work has found that the intensity of perceived allodynic pain correlates with activation in the anterior insula, but the peak of activation during allodynia sits in a different sub-region (the rostral anterior insula) compared to where experimental pain peaks in healthy volunteers (the caudal anterior insula). This pattern matches other chronic pain syndromes, suggesting a functional shift in how the insula processes pain once it becomes pathological.²⁹ Spontaneous ongoing pain and touch-evoked allodynia in the same patients activate overlapping brain areas but with minimal overlap at the specific voxel level, implying that even though both feel like “pain from shingles,” the brain processes them through partly separate networks.³⁰

Sleep Loss and Allodynia

Poor sleep does not just make pain feel worse in a vague subjective way. It actively lowers pain thresholds and promotes allodynia. In animal experiments, sleep deprivation before an inflammatory insult significantly enhanced the resulting allodynia, and the combination of sleep loss and inflammation produced a synergistic effect, meaning the allodynia was worse than either factor would predict on its own. The heightened pain sensitivity persisted for weeks.³¹ Even selective loss of REM sleep, the dreaming phase, is enough to induce tactile allodynia in otherwise healthy rats. This appears to involve specific chloride channels in the spinal cord that maintain their pro-pain role in both males and females, though the expression patterns differ by sex.³²

For people living with allodynia from any cause, this creates a vicious cycle. Pain disrupts sleep, and disrupted sleep amplifies allodynia, which further disrupts sleep. Addressing sleep quality is not just a nice-to-have; it can be a meaningful lever for reducing pain sensitivity. This is one reason comprehensive pain management programs increasingly include sleep hygiene interventions and, when needed, treatment for sleep disorders alongside pain-directed therapies.

Genetic Variation and Individual Susceptibility

Not everyone with nerve damage develops allodynia, which points to genetic variation in pain susceptibility. One of the most studied targets is the SCN9A gene, which codes for a sodium channel called Nav1.7. Mutations in this gene cause dramatic effects on pain perception: some mutations lead to severe inherited pain syndromes, while loss-of-function mutations cause a congenital inability to feel pain in people who are otherwise neurologically normal.³³ Nav1.7 has been a major drug development target for chronic pain, though translating this genetic insight into effective therapies has proven more difficult than researchers initially hoped. Multiple clinical trials of Nav1.7 blockers have produced mixed results, suggesting that real-world pain involves more redundancy and complexity than a single-channel target can address. Still, the genetics confirm that susceptibility to allodynia and other forms of pain hypersensitivity has a biological basis that varies from person to person, which helps explain why two people with similar nerve injuries can have dramatically different pain outcomes.